Condition: ASC-US · LSIL · Sponsor: University of Alabama at Birmingham
Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
This description comes directly from the study's public registry record.
Wendy Wu, MS · +886 2 8226 8451 · wendy@papivax.com.tw
Yung-Nien Chang, Ph.D. · 410-804-9662 · changyn@papivax.com
Always discuss trial participation with your own doctor first.
| UAB | The University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03913117